CLDX
Celldex Therapeutics, Inc.
Key Financials
EPS (Diluted)
$-3.90
↓ 59.2%
Revenue
$1.5M
↓ 78.0%
Net Income
$-258757000
↓ 63.9%
Total Liabilities
$55.8M
↑ 23.1%
Total Assets
$583.0M
↓ 26.4%
Cash & Equivalents
$28.9M
↑ 1.8%
Operating Income
$-287367000
↓ 47.3%
Shareholders' Equity
$527.2M
↓ 29.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CLDX |
| Company Name | Celldex Therapeutics, Inc. |
| CIK | 744218 |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 908-200-7500 |